Haematologica HAEMATOL/2016/151449 Version 2

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

Vikas Gupta, Claire Harrison, Elizabeth O. Hexner, Haifa Kathrin Al-Ali, Lynda Foltz, Michael Montgomery, William Sun, Prashanth Gopalakrishna, Hagop Kantarjian, and Srdan Verstovsek

Disclosures: VG: (Incyte) research funding, honoraria; (Novartis) consultancy, research funding, honoraria, advisory board participation. CH: (CTI BioPharma Corp) consultancy, honoraria, speakers bureau; (Gilead) speakers bureau; (Novartis) research funding, honoraria, speakers bureau; (Sanofi) honoraria; (Shire) honoraria, speakers bureau; (Baxalta) honoraria, speakers bureau. EOH: nothing to disclose. HKA: (Celgene) research funding, consultancy, honoraria; (Novartis) research funding, consultancy, honoraria. LF: (Gilead) research funding; (Novartis) research funding, honoraria; (Promedior) research funding. MM: (Incyte) employment and equity ownership. WS: (Incyte) employment and equity ownership. PG: (Novartis Pharma AG) employment. HK: (Incyte) research funding. SV: (AstraZeneca) research funding; (BMS) research funding; (Celgene) research funding; (CTI BioPharma Corp.) research funding; (Geron) research funding; (Gilead) research funding; (NS Pharma Inc.) research funding; (Pfizer) research funding; (Promedior) research funding; (Roche) research funding; (Seattle Genetics) research funding.

Contributions: VG cared for patients, collected data, interpreted data, collaborated on writing the manuscript and approved the final draft. CH, EOH, HKA, LF, HK and SV cared for patients, collected data, collaborated on writing the manuscript and approved the final draft. MM collaborated on writing the manuscript and approved the final draft. WS and PG analysed and interpreted the data, collaborated on writing the manuscript and approved the final draft. All authors had access to study results and full control over the content of the manuscript.